research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata
Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
Search
for
Sort by
Research
180-210 / 266 results
research Lichen Planopilaris and Frontal Fibrosing Alopecia: Review and Update of Diagnostic and Therapeutic Features
The document concludes that more research is needed to find effective treatments for Lichen planopilaris and Frontal fibrosing alopecia.
research How Our Microbiome Influences the Pathogenesis of Alopecia Areata
Our microbiome may affect the development of the hair loss condition Alopecia Areata, but more research is needed to understand this relationship.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarriers Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research Unveiling a Shared Precursor Condition for Acne Keloidalis Nuchae and Primary Cicatricial Alopecias
A condition with certain scalp changes may come before acne keloidalis nuchae and other similar hair loss disorders.
research Hydrogel Forming Microneedles Loaded With VEGF and Ritlecitinib/Polyhydroxyalkanoates Nanoparticles for Mini-Invasive Androgenetic Alopecia Treatment
New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report
A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
research Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
New understanding and treatments for hair loss are improving, but more research is needed.
research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Treating Alopecia Areata: Current Practices Versus New Directions
New treatments like JAK inhibitors show promise for reversing alopecia areata.
research Alopecia Areata: Medical Treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Building and Crossing the Translational Bridge: 2016 Alopecia Areata Research Summit Highlights
The summit aimed to speed up finding treatments for alopecia areata.
research Oral Tofacitinib in Moderate and Severe Alopecia Areata: Case Series of 14 Patients
Tofacitinib helped regrow hair in most patients with severe hair loss.
research IKZF1 and IKAROS Overexpression Contributes to the Pathogenesis of Alopecia Areata
Too much IKZF1 and Ikaros protein may cause alopecia areata.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Effect of Tofacitinib on the Expression of Noggin/BMP-4 and Hair Growth Stimulation in Mice
Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
research Alopecia Areata: Diagnostic and Therapeutic Recommendations of the Polish Society of Dermatology. Part 2: Treatment
The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
research Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
research The Frontal Fibrosing Alopecia Treatment Dilemma
Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata
CD8+ T cells are involved in alopecia areata and may cause disease relapse.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research In-Silico Screening of ATP-Competitive Inhibitory Activities of Phytochemicals Against Janus Kinase 3 and Its In-Vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.